( AMEX:PIP )

News from pharmathene, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 13, 2016, 08:03 ET PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy

PharmAthene, Inc. (NYSE MKT: PIP) reported today that the U.S. Bankruptcy Court for the Southern District of New York approved a reorganization...


Mar 11, 2016, 16:30 ET PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax and owner of an affirmed judgment...


Dec 24, 2015, 08:00 ET Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award...


Dec 15, 2015, 18:20 ET PharmAthene Reports that SIGA has Filed its Reorganization Plan to Exit from Bankruptcy

 PharmAthene, Inc. (NYSE MKT: PIP) reported today that SIGA Technologies, Inc. filed with the U.S. Bankruptcy Court for the Southern District...


Nov 25, 2015, 16:11 ET PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards

 PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its Board of Directors has adopted a stockholder rights plan (Rights Plan) in an...


Nov 06, 2015, 16:00 ET PharmAthene Reports Third Quarter 2015 Financial and Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its...


Oct 07, 2015, 17:28 ET PharmAthene Announces Conclusion of Oral Arguments In Its Litigation Against SIGA

PharmAthene, Inc. (NYSE MKT: PIP)  announced that oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the Delaware...


Aug 05, 2015, 17:00 ET PharmAthene Reports Second Quarter 2015 Financial and Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its...


May 07, 2015, 16:01 ET PharmAthene Reports First Quarter 2015 Financial and Operational Results

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...


Apr 13, 2015, 08:03 ET PharmAthene Receives $5.8 Million Payment From BARDA

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that on April 9, 2015, it received from the Biomedical Advanced Research and Development...


Mar 09, 2015, 16:00 ET PharmAthene Reports Year-End 2014 Financial And Operational Results; Announces Plan To Realign Operational Resources

  2014 Operational Highlights - Delaware Court of Chancery issues final judgment granting lump sum award to PharmAthene totaling...


Feb 02, 2015, 10:15 ET PharmAthene rPA Antigen Formulated With DepoVax™ Demonstrates Promise As Single Unit Dose Anthrax Vaccine

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that its recombinant Protective Antigen (rPA) was one of the vaccines reported by...


Jan 15, 2015, 16:08 ET PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the...


Jan 07, 2015, 14:18 ET Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million

PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has issued a letter Opinion and Order directing PharmAthene...


Nov 20, 2014, 10:15 ET PharmAthene Fulfills Valortim® IDIQ Contract

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats,...


Nov 06, 2014, 16:02 ET PharmAthene Provides Third Quarter 2014 Operational And Financial Update

Recent Operational Highlights - Awarded NIAID contract for next generation anthrax vaccine program valued up to $28.1 million -...


Oct 08, 2014, 12:30 ET PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment

 PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially...


Sep 10, 2014, 09:03 ET PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...


Sep 09, 2014, 09:03 ET New Non-Clinical Data Demonstrate SparVax® Provides Equivalent Protection In Head-To-Head Comparison With BioThrax®

PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax® anthrax vaccine program were...


Sep 08, 2014, 12:33 ET PharmAthene To Present At Rodman & Renshaw And Aegis Capital Corporation 2014 Investment Conferences

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...


Sep 08, 2014, 10:13 ET PharmAthene and Nanotherapeutics Form Strategic Alliance to Advance Biodefense Programs

 PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have...


Aug 10, 2014, 07:13 ET Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and...


Aug 04, 2014, 16:02 ET PharmAthene Reports Second Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...


Jun 09, 2014, 10:30 ET PharmAthene Granted U.S. Patent For Recombinant Bioscavenger

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to...


Jun 04, 2014, 10:30 ET PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014...